Friday, February 16, 2018 10:53:16 AM
February 15, 2018 | About: CDXS +0%
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the molecular diagnostics industry by developing and commercializing high-performance enzymes for use in next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) applications. Clairmont will be responsible for all commercial activities related to the molecular diagnostics enzyme product line, including product launches and market and pricing strategies. She reports to Michael Aldridge, Codexis’ Senior VP Corporate & Strategic Development.
“We welcome Shawn to Codexis as we prepare to commercially launch our first high-performance enzymes for the molecular diagnostics industry,” said Aldridge. “Shawn brings us significant global experience in product launches and commercial account management as well as established relationships with key molecular diagnostic firms and industry opinion leaders. We look forward to calling upon her expertise in developing successful strategies as we bring new enzymes into this established market.”
Warning! GuruFocus has detected 6 Warning Signs with CDXS. Click here to check it out.
CDXS 30-Year Financial Data
The intrinsic value of CDXS
Peter Lynch Chart of CDXS
“This is an exciting time in molecular diagnostics as new technologies, such as liquid biopsy, create the need for high-performance enzymes,” said Clairmont. “Codexis is uniquely positioned to use its CodeEvolver® protein engineering platform to develop enzymes aimed at improving the sensitivity and precision of these tests in identifying biomarkers of interest. I’m delighted to join the Codexis team.”
Clairmont has 13 years of molecular diagnostics industry experience. Most recently she served as Chief Operating Officer of BRIDGenomics, a molecular diagnostics and medical device marketing consultancy providing business development and strategic marketing expertise. She previously served for eight years at the molecular diagnostics company QIAGEN in a variety of positions with increasing responsibility, most recently as Director of Sales, America, on the Global Advanced Molecular Pathology Team. Prior to QIAGEN, Clairmont was a technical marketing representative and account manager at bioArray Solutions LTD. She holds an MBA from the College of Saint Scholastica in Duluth, Minn. and a BA in biology from Saint Olaf College in Northfield, Minn.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Recent CDXS News
- Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting • GlobeNewswire Inc. • 08/20/2024 08:05:36 PM
- Codexis Announces New Employment Inducement Grants • GlobeNewswire Inc. • 08/16/2024 08:05:09 PM
- Codexis Publishes FY2023 Sustainability Disclosures • GlobeNewswire Inc. • 08/15/2024 08:05:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 08:01:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:17:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:07:54 PM
- Codexis Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Codexis to Report Second Quarter 2024 Financial Results on August 8 • GlobeNewswire Inc. • 07/18/2024 08:05:11 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/12/2024 08:15:13 PM
- Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets • GlobeNewswire Inc. • 07/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:28:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:28:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:27:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:27:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:27:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:26:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:25:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:04:54 PM
- Codexis to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2024 08:25:41 PM
- Codexis to Participate in TD Cowen 2nd Annual Sustainability Week • GlobeNewswire Inc. • 05/20/2024 08:05:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2024 01:11:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 10:52:02 AM
- Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting • GlobeNewswire Inc. • 05/14/2024 10:00:00 AM
- Codexis Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Codexis to Report First Quarter 2024 Financial Results on May 2 • GlobeNewswire Inc. • 04/18/2024 08:05:10 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM